US20060247297A1

US20060247297A1 - Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases

Info

Publication number: US20060247297A1
Application number: US10/537,824
Authority: US
Inventors: Marcello Allegretti; Riccardo Bertini; Cinzia Bizzarri; Maria Cesta; Francesco Colotta
Original assignee: Individual
Current assignee: Dompe SpA
Priority date: 2002-12-10
Filing date: 2003-12-09
Publication date: 2006-11-02
Also published as: US9328057B2; CA2507765A1; PT1581474E; AU2003289993A1; SI1581474T1; CN100383110C; EP1581474B1; CN1732145A; RU2345759C2; CA2507765C; AU2003289993B8; JP5021169B2; EP1581474A1; AU2003289993B2; HK1085721A1; ATE406343T1; WO2004052830A1; DK1581474T3; JP2006509022A; NO20053086L

Abstract

The compounds of formula (I):

where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia and reperfusion.

Description

The present invention relates to chiral arylketones, a process for their preparation, and pharmaceutical compositions containing them, which are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleate neutrophils in the inflammatory sites.
Other classes of compounds, such as R-2-arylpropionic acid amides and N-acylsulfonamides useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleate neutrophils in the inflammatory sites, have been described in WO 01/58852 and WO 00/24710 respectively.
The compounds of the invention are generally known compounds and disclosed in Belstein Handbook of Organic Chemistry.

DETAILED DESCRIPTION OF THE INVENTION

More specifically, the present invention relates to chiral arylketones of general formula I:

wherein:

Ar is an aryl group;
Ra and Rb are independently chosen in the group of hydrogen, linear or branched C₁-C₆alkyl, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₁-C₄-alkylphenyl, C₁-C₄-alkyl(α-or β-naphthyl), C₁-C₄-alkyl(2,3,4-pyridyl), cyano(—CN), carboxyamide, carboxyl or carboxyesters of formula CO₂R″ wherein R″ is the residue of a linear or branched C₁-C₆aliphatic alcohol, a phosphonate PO(OR″)₂wherein R″ is as defined above, a group of formula di-X—(CH₂)_n-Z, wherein X is a CO, SO, SO₂group; Z is H, tert-butyl, isopropyl, CO₂R″, CN, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₃-C₆cycloalkyl, NH-BOC, NH₂;
n is zero or an integer from 1 to 3; or Ra and Rb, with the carbon atom to which they are bound, form a cyclic residue 4,6-dioxo-1,3-dioxanyl-2,2-disubstituted of formula II: branched C₁-C₆aliphatic alcohol, a phosphonate PO(OR″)₂where R″ is as defined above, a group of formula —X—(CH₂)_n-Z, wherein X is a CO, SO, SO₂group; Z is H, tert-butyl, isopropyl, CO₂R″, CN, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₃-C₆cycloalkyl, NH-BOC, NH₂; n is zero or an integer from 1 to 3;
or Ra and Rb, with the carbon atom to which they are bound, form a cyclic residue 4,6-dioxo-1,3-dioxanyl-2,2-disubstituted of formula II:

wherein R′ is methyl or ethyl, or the two groups R′ form a cyclohexane or cyclopentane ring, in the preparation of a medicament for the treatment of diseases that involve IL-8 induced human PMNs chemotaxis.
2. Use of compounds according to claim 1 wherein Ar represents a residue 4-isobutyl-phenyl, 3-benzoyl-phenyl, 5-benzoyl-phenyl, 2-acetoxy-phenyl, 3-phenoxy-phenyl.
3. Use of compounds according to claims 1 or 2 selected from:
methyl(R)(−)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate;
methyl(S)(+)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate;
(R,S)4-[(4′-isobutyl)phenyl]-3-oxopentanoic acid;
methyl(R)(−)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate;
(R)(−)-3-[(4′-isobutyl)phenyl]butan-2-one;
(S)(+)-3-[(4′-isobutyl)phenyl]butan-2-one;
(R)(−)-3-[(3′-benzoyl)phenyl]butan-2-one;
(R)(−)-dimethyl 3-(4-isobutyl-phenyl)-2-oxobutan-1-phosphonate;
(S)(±)-dimethyl 3-(3′-phenoxy-phenyl)-2-oxo-butyl-1-phosphonate;
(R)(−)-2-(4-isobutylphenyl)-pentan-3-one;
(S)(+)ethyl-4-[(3′-benzoyl)phenyl]-3-oxopentanoate;
(S)(+)-3-[(3′-benzoyl)phenyl]butan-2-one;
(R)(−)-2-(4-isobutylphenyl)-4-phenyl-butan-3-one;
(R)(−)-2-(4-isobutylphenyl)-5-phenyl-pentan-3-one;
(R)(−)-2-(4-isobutylphenyl)-5-(pyrid-3-yl)-pentan-3-one;
(R,S)5-(4′-isobutylphenyl)-hexan-2,4-dione;
(R,S)1-phenyl-5-(4′-isobutylphenyl)-2,4-hexandione;
(R,S)1-(pyrid-2-yl)-4-(4′-isobutylphenyl)-1,3-pentadione;
(R)(−)2-(4-isobutylphenyl)-7-tert-butoxycarbonylamino-heptan-3-one;
(RS)2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfoxide;
(R,S)2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfoxide;
(R,S)2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfone;
(RS)2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfone;
(R,S)2-(3′-phenoxyphenyl)-3-oxo-butyl, methyl-sulfone;
(R,S)2-(4′-isobutylphenyl)-3-oxo-butyl, phenyl-sulfone;
(R)(−)-4-(4′-pyridyl)-2-[(4″-isobutyl)phenyl]butan-3-one;
(R)(+)-5-[2-(4-isobutyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione;
(R)(−)-5-[2-(3′-benzoyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione.
(R)-2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeramide;
(R)-2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeronitrile;
4. Use of compounds:
(R)(−)methyl 4-[(4′-benzoyloxy)phenyl]-3-oxopentanoate,
(R)(−)methyl-4-[(4′-isopropylsulfonyloxy)phenyl]-3-oxopentanoate and
(R)(−)methyl-4-{[4′-(2″-ethyl)phenylsulfonylamino]phenyl}-3-oxopentanoate, in the preparation of a medicament for the treatment of diseases that involve IL-8 induced human PMNs chemotaxis.
5. Use of compounds according to Claims 1 or 2, wherein the steric configuration of the carbon atom to which the residue Ar is bound corresponds to the enantiomer (R).
6. Pharmaceutical compositions containing a compound according to any one of Claims 1 to 5 in admixture with a suitable carrier thereof.
7. Use of the compounds according to any one of Claims 1 to 5 in the preparation of medicaments for the treatment psoriasis, rheumatoid arthritis, ulcerative cholitis, acute respiratory distress syndrome (ARDS), idiopathic fibrosis, glomerulonephntis, bollous pemphigo and for the prevention and the treatment of damages caused by ischemia and reperfusion.

A β-ketoester of formula Ia and Ic may optionally be dealkoxydecarboxylated to the corresponding arylketone of formula I by simply heating in an aprotic solvent (preferably dimethylsulfoxide) in the presence of small amounts of water and, optionally, of small amounts of electrolytes, such as NaCl, NaCN, LiCl, LiI (according to J. P. Krapcho, Synthesis 805 and 893, 1982, and references cited herein). Likewise, using well known methods, a compound of formula Ia can be converted into another compound of formula I by removal of any protective groups that may be present, or by saponification of carboxyl groups, or by conversion of nitriles into carboxyamides.
The compounds of formula IV are obtained in a conventional way, conserving their enantiomeric integrity, starting from the individual enantiomers of the 2-aryl-propionic acids of formula IVa:

which are known compounds and can be obtained from the individual racemates using known methods of optical resolution.
The preparation of the carbanions of formula V consists in a process of C-acylation in virtually neutral conditions, fully described in the literature (see, for example, D. W. Brooks et al., Angew. Chem. Int. Ed. Engl., 18, 72, 1979), as well as monoesters of malonic acids and of monosubstituted malonic acids, also on sulfinylacetic acids, sulfonylacetic acids and phosphonoacetic acids. All these acids are known in the literature or can be prepared using known methods, such as monosaponification of diesters of which are known compounds and can be obtained from the individual racemates using known methods of optical resolution.
The preparation of the carbanions of formula V consists in a process of C-acylation in virtually neutral conditions, fully described in the literature (see, for example, D. W. Brooks et al., Angew. Chem. Int. Ed. Engl., 18, 72, 1979), as well as monoesters of malonic acids and of monosubstituted malonic acids, also on sulfinylacetic acids, sulfonylacetic acids and phosphonoacetic acids. All these acids are known in the literature or can be prepared using known methods, such as monosaponification of diesters of malonic acids and their monosubstituted analogues or saponification of phosphonoacetic acids and 2-substituted analogues; sulfinylacetic and sulfonylacetic acids may be obtained by oxidation of ethers of thioglycolic acid. Alternatively, it is possible to use lithium enolates of formula V, obtained by reaction of lithium alkyls with known alkyl esters of alkylphosphonates (see, for example, N. Mongelli et al., Synthesis, 310, 1988) or with esters of acetic acid (according to D. H. Harris et al., Tetrah. Lett., 28, 2837, 1987).
For the preparation of enolates of formula Va, and more generally for the procedure of acylation of the cyclic alkylidenesters of malonic acid (also known as Meldrum acids) with the activated species of a carboxyl of formula IV, the method described by Y. Oikawa et al., J. Org. Chem., 43, 2087 (1978), R. P. Houghton and D. J. Lapham, Synthesis 451 (1982) and C. C. Chan and X. Hung, ibidem, 452 (1982) is used.
The preparation of dialkoxyphosphonoacetic acids and that of their esters are exemplified in U.S. Pat. No. 4,151,172 (Apr. 24, 1979), or described by R. A. Malevannaya et al., in Zh. Obshch. Khim. 41, 1426 (1971).
Specific examples of the compounds of the invention are:

methyl(R)(−)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate;
methyl(S)(+)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate;
(R,S)4-[(4′-isobutyl)phenyl]-3-oxopentanoic acid;
methyl(R)(−)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate;
(R)(−)-3-[(4′-isobutyl)phenyl]butan-2-one;
(S)(+)-3-[(4′-isobutyl)phenyl]butan-2-one;
(R)(−)-3-[(3′-benzoyl)phenyl]butan-2-one;
(R)(−)-dimethyl 3-(4-isobutyl-phenyl)-2-oxobutan-1-phosphonate;
(S)(±)-dimethyl 3-(3′-phenoxy-phenyl)-2-oxo-butyl-1-phosphonate;
(R)(−)methyl-4-{[4′-(2″-ethyl)phenylsulfonylamino]phenyl}-3-oxopentanoate;
(R,S)5-(4′-isobutylphenyl)-hexan-2,4-dione;
(R,S)1-phenyl-5-(4′-isobutylphenyl)-2,4-hexandione;
(R,S)1-(pyrid-2-yl)-4-(4′-isobutylphenyl)-1,3-pentadione;
(R)(−)2-(4-isobutylphenyl)-7-tert-butoxycarbonylamino-heptan-3-one;
(R,S)2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfoxide;
(R,S)2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfoxide;
(R,S)2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfone;
(R,S)2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfone;
(R,S)2-(3′-phenoxyphenyl)-3-oxo-butyl, methyl-sulfone;
(R,S)2-(4′-isobutylphenyl)-3-oxo-butyl, phenyl-sulfone;
(R)(−)-4-(4′-pyridyl)-2-[(4″-isobutyl)phenyl]butan-3-one;
(R)-2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeramide;
(R)-2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeronitrile;
(R)(+)-5-[2-(4-isobutyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione;
(R)(−)-5-[2-(3′-benzoyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione.

The compounds of formula I are powerful inhibitors of the chemiotaxis of the neutrophils induced by IL-8 and inhibit the amplification of the production of TNF-α stimulated by lipopolysaccharides and by hydrogen peroxide. An exacerbated production of hydrogen peroxide is notoriously the final consequence of the neutrophilic activation consequent upon a chemiotactic stimulus.
Examples of β-ketoesters of formula I are methyl R(−)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate and methyl R(−)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate, which, at the concentration of 10⁻⁸M, inhibit the chemiotaxis of human neutrophils to an extent higher than 50% as compared to control values.
A typical example of 2-aryl-alkan-3-one is R(−)-3-[(4′-isobutyl)phenyl]butan-2-one for which an IC₅₀of 5.10⁻¹⁰M has been calculated in the same in vitro inhibition assay.
For evaluation of the compounds of the invention, polymorphonucleated blood cells were used obtained from heparinized blood of healthy adult volunteers by means of sedimentation on dextran. The mononucleated cells were removed by means of Ficoll/Hypaque, whilst the red blood cells were eliminated by treatment with hypotonic solutions. The cell vitality of the polymorphonucleated leucocytes (PMNs) was calculated by means of exclusion with Turk and Trypan Blue whilst after staining with Diff Quinck the percentage of the PM-nucleates on the cytocentrifugate was estimated (for details of the experimental techniques used see W. J. Ming et al., J. Immunol., 138, 1469, 1987).
In each of the in vitro experiments, time periods of 10 minutes were used for the incubation of the PMNs with the compounds of the invention, operating at a temperature of 37° C.
In the experiments of chemiotaxis and in those designed for measuring the cytosol levels of the Ca²⁺ ion, human recombinant IL-8 (Pepro Tech.) was used as stimulant: the liophilized protein was dissolved in HBSS (Hank's balanced salts solution) at a concentration of 100 ng/mL and was used after dilution in HBSS down to concentrations of 10 ng/mL in the chemiotaxis experiments and at the concentration of 25-50 ng/mL in the evaluation of the modifications of [Ca²⁺].
In the chemiotaxis assay (according to W. Falket et al., J. Immunol. Methods, 33, 239, 1980) PVP filters were used having a porosity of 5 μm and a Plexiglas microchamber suitable for making 48 replications. The microchamber consists of a block of Plexiglas containing 48 wells, each having a capacity of 25 μL and is provided with a lid, which in turn contains 48 pores arranged in such a way that, once the lid has been set in place and screwed to the underlying part, it comes to form the top compartments of the microchamber, each having a capacity of 50 μL.
The compounds under study were added at one and the same concentration in the wells of higher level, which contain the suspension of PMNs and in the wells of lower level, which contain the vehicle to which IL-8 (or a different stimulant) has been added or not.
For determination of the cytosol variations of the [Ca²⁺]_i, the experimental model described by C. Bizzarri et al., (Blood, 86, 2388, 1995) was adopted, using slides containing adhered PMNs, which were fed with 1 μM of Fura-2AM in order to evaluate said variations of [Ca²⁺]_iin real time. In turn, cytocentrifugates of PMNs were resuspended in RPMI medium 1640 with 5% of FCS (foetal cow serum) at a concentration of 3×10⁶/mL and then plated on round glass slides of a diameter of 25 mm, which were placed in an incubator for 30 min at 37° C. After three consecutive washings with balanced salts solution (BSS) to remove the non-adherent cells, a further incubation was performed for the set of adherent cells for a maximum of 4 hours before feeding with Fura-2AM.
The compounds of the invention prevent the increase in the intracellular concentration of Ca²⁺ induced by IL-8.
The compounds of the invention are characterized by their capacity for inhibiting in vitro the chemiotaxis of the human PMN leucocytes (PMNs) stimulated by interleukin 8, also known as “monocyte-derived neutrophil-activating protein” (NAP/IL-8 or more simply IL-8). Said inhibition is dose-dependent, with values of IC₅₀(dose inhibiting 50% of the effect) in the 10⁻⁷to 10⁻⁹-M range; the inhibiting effect is selective and specific in regard to the chemiotactic stimulus induced by IL-8. Concentrations higher by one or two orders of magnitude are needed to inhibit the chemiotaxis stimulated in vitro by other chemiotactic factors (C5a, formylpeptides of bacterial origin or synthetic origin, such as f-LMP). The specificity of the compounds of the invention is moreover demonstrated by their capacity to inhibit the increase in the intracellular concentration [Ca²⁺]_iin human PMNs, an increase that is associated to the activation of the human PMNs themselves by IL-8 [J. H. Liu et al., J. Infect. Dis., 166, 1089 (1992)].
Independently of the absolute configuration, the compounds of the invention are without significant effects on cyclooxygenasis and on the production of PG.
In fact, in murine macrophages stimulated by LPS (1 μg/mL), the compounds of the invention (evaluated in the range of concentration of 10⁻⁵to 10⁻⁷M) show an inhibition of the production of PGE₂which, albeit frequently at the limit of statistical significance, is never higher than 10 to 15% of the basal value.
The above minor inhibition of the synthesis of PGE₂involves the advantage, unlike what occurs for certain 2-aryl-propionic acids, of not constituting a stimulus that is likely to amplify the synthesis of TNF-α by the murine macrophages themselves (once they have been stimulated by LPS). The amplification of the synthesis of TNF-α is considered to concur, in turn, in amplifying the activation and chemiotaxis of the neutrophils and the synthesis of IL-8. On the other hand, these effects of non-amplification of the synthesis of TNF-α are shown also in regard to the synthesis of TNF-α stimulated by hydrogen peroxide.
It is known that interleukin 8 (IL-8) and the correlated cytokines are the most important modulators of the infiltration of the neutrophils in diseases such as psoriasis (B. J. Nickoloff et al., Am. J. Pathol., 138, 129, 1991), rheumatoid arthritis (M. Selz et al., J. Clin. Invest. 87, 463, 1991), ulcerative cholitis (Y. R. Mahkla et al., Clin. Sci., 82, 273, Nickoloff et al., Am. J. Pathol., 138, 129, 1991), rheumatoid arthritis (M. Selz et al., J. Clin. Invest. 87, 463, 1991), ulcerative cholitis (Y. R. Mahkla et al., Clin. Sci., 82, 273, 1992), acute respiratory distress syndrome (ARDS), idiopathic fibrosis (P. C. Carré et al., J. Clin. Invest., 88, 1802, 1991 and E. J. Miller et al., Am. Rev. Respir. Dis., cited above), glomerulonephritis (T. Wada et al., J. Exp. Med., 180, 1135, 1994) and bollous pemphigo. The compounds of the invention are then used for the treatment of said diseases, conveniently formulated in pharmaceutical compositions using conventional techniques and excipients.
The compounds of the invention are also conveniently used for the prevention and the treatment of damages caused by ischemia and reperfusion, in particular in connection with organ transplantation.
The compositions of the invention can be administered via intramuscular injection, via intravenous route, as a bolus, in preparations for dermatological use (creams, lotions, sprays and ointments), as well as via oral route in the form of capsules, tablets, syrup, controlled-release formulations, and the like.
The mean daily dosage will depend upon various factors, such as the severity of the illness and the conditions of the patient (age, sex and weight). The dose will vary generally from one mg or a few mg up to 1500 mg of the compounds per day, optionally divided into multiple administrations. Higher dosages, as well as more prolonged treatment times, can be administered also by virtue of the low toxicity of the compounds of the invention.
The following examples are provided by way of illustration of the invention. The examples are not construed to be viewed as limiting the scope of the invention.

EXAMPLE 1

(R)(−)-3-[(4′-isobutyl)phenyl]butan-2-one

(R)(−)-ibuprofen (2 g, 9.69 mmol) is dissolved in thionyl chloride (4 mL), and the solution obtained is refluxed for 4 hours.
After cooling to room temperature, the solvent is evaporated at reduced pressure, and the excess of thionyl chloride is eliminated by dissolving the residue twice with dioxane and evaporating the solvents at a high vacuum. The oily yellow residue (2.34 g; 9.34 mmol) thus obtained, is dissolved in dry dichloromethane (3 mL) and added, by means of slow dripping and in an inert-gas atmosphere, to a solution of 2,2-dimethyl-1,3-dioxan-2,5-dione (Meldrum's acid) (1.35 g; 9.34 mmol) and pyridine (1.83 mL; 22.9 mmol) in dry dichloromethane (7.5 mL) previously cooled to 0-5° C. with a water/ice bath. Once the additions are completed, the product is left for one hour at this temperature and then for another hour at room temperature. The mixture diluted with dichloromethane is partitioned with a 2N HCl and crushed ice, under vigorous stirring for 30 min. After separation of the phases, the organic phase, washed with 2N HCl (2×10 mL) and with a saturated solution of NaCl, is dried on Na₂SO₄. After evaporation of the solvents at reduced pressure, 2.69 g of R(+)-5-[2-(4-isobutyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione is obtained as an oil. ([α_D]=+61.7°; c=1% CH₂Cl₂) which, without further purifications, is dissolved in dioxane (10 mL). Glacial acetic acid (0.84 mL) and water (0.13 mL) are added, and the resulting solution is heated to the reflux temperature for 3 hours. After cooling and evaporation of the solvents, the residue is purified by means of flash chromatography (eluent: n-hexane/ethyl ether 9:1) to yield (R)(−)-3-[(4′-isobutyl)phenyl]butan-2-one as a pale yellow oil (0.97 g; 4.75 mmol).
[α]_D=−216.1° (c=1; CH₃CH₂OH); ¹H-NMR (CDCl₃): δ 6.95 (s, 4H); 3.61 (q, 1H, J=8 Hz); 2.3 (d, 3H, J=7 Hz); 1.93 (s, 3H); 1.75 (m, 1H); 1.26 (d, 2H, J=8 Hz); 0.85 (d, 6H, J=7 Hz).

EXAMPLE 2

(S)(+)-3-[(4′-isobutyl)phenyl]butan-2-one;

(R)(−)-3-[(3′-benzoyl)phenyl]butan-2-one;

Following the procedure of Example 1, using 0.3 g (1.33 mmol) of S(+)-ibuprofen, S(+)-3-[(4′-isobutyl)phenyl]butan-2-one is obtained (0.13 g, 0.63 mmol) as a pale yellow oil;
[α]_D=+210.5 (c=1; CH₃CH₂OH); ¹H-NMR (CDCl₃); δ 7.10 (s, 4H); 3.75 (q, 1H, J=8 Hz); 2.45 (d, 3H, J=7 Hz); 2.05 (s, 3H); 1.85 (m, 1H); 1.32 (d, 2H, J=8 Hz); 0.92 (d, 6H, J=7 Hz). Likewise, starting from 0.74 g (2.9 mmol) of (R) (−)-ketoprofen, 0.46 g (1.79 mmol) of R(−)-3-[(3′-benzoyl)phenyl]butan-2-one are obtained as a yellow oil; [α]_D=−103° (C=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.85 (m, 2H); 7.75 (m, 2H); 7.60 (m, 1H); 7.55-7.40 (m, 4H); 3.85 (q, 1H, J=8 Hz); 2.1 (s, 3H); 1.45 (d, 3H, J=8 Hz).

EXAMPLE 3

methyl(R)(−)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate

4-[(4′-isobutyl)phenyl]-3-oxopentanoic acid

(R)(−)-ibuprofen (1.2 g, 5.8 mmol) is dissolved in dioxane (5 mL); thionyl chloride (2.36 mL) is added and the solution obtained is refluxed and left to reflux for 3 hours. After cooling to room temperature, the solvent is evaporated at reduced pressure, and the excess of thionyl chloride is eliminated, dissolving the residue twice with dioxane and evaporating the solvents under high vacuum. An oily yellow residue (1.3 g; 5.79 mmol) is obtained, which is dissolved in dry dichloromethane (2 mL) and added, by means of slow dripping and in an inert atmosphere, to a solution of 2,2-dimethyl-1,3-dioxan-2,5-dione (Meldrum's acid) (0.83 g; 5.79 mmol) and pyridine (1.12 mL; 14 mmol) in dry dichloromethane (5 mL) previously cooled to T=+5° C. with a water/ice bath. Once the additions are completed, the mixture is left for one hour at this temperature and then for another hour at room temperature. The mixture, diluted with dichloromethane is repartitioned with a 2N solution of HCl and crushed ice, under vigorous stirring for approximately 30 min. After separation of the phases, the organic phase, washed with 2N HCl (2×10 mL) and with a saturated solution of NaCl, is dried on Na₂SO₄. fter evaporation of the solvent at reduced pressure, the residue of (R)(+)-5-[2-(4-isobutyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione ([α]_D=+62°; c=1.1% CH₂Cl₂) without further purifications, is dissolved in methanol (14 mL); the solution is reheated to reflux for 3 hours. After cooling and evaporation of the solvent, the residue is purified by means of flash chromatography (eluent: n-hexane/ethyl ether 8:2) to yield pure methyl ester of (R)(−)-4-[(4′-isobutyl)phenyl]-3-oxopentanoic acid as a colourless oil (0.6 g; 2.28 mmol); [α]_D=−192.5° (c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.1 (s, 4H); 3.88 (q, 1H, J=8 Hz); 3.67 (s, 3H); 3.47-3.28 (q, 2H, J=8 Hz); 2.45 (d, 2H, J=8 Hz); 1.85 (m, 1H); 1.40 (d, 3H, J=8 Hz); 0.95 (d, 6H, J=7 Hz).
To a solution in methanol (2 mL) of 0.15 g (0.57 mmol) of said ester is added a solution of 1N NaOH (1 mL); and the mixture is stirred at room temperature overnight. The solvents are then evaporated at reduced pressure; the residue is dissolved with water (3 mL), and 2N HCl is added by dripping up to pH=1 the mixture is then extracted with ethyl ether (3×10 mL); the organic phase is then washed with a saturated solution of NaCl (10 mL), dried on Na₂SO₄, and evaporated at reduced pressure to yield 0.12 g (0.48 mmol) of pure (+)4-[(4′-isobutyl)phenyl]-3-oxopentanoic acid, as a colourless oil;
¹H-NMR (CDCl₃): δ 7.1 (m 4H); 3.88 (q, 1H, J=8 Hz); 3.45 (m, 2H); 2.48 (d,, 2H, J=8 Hz); 1.90 (m,1H); 1.45 (d, 3H, J=8 Hz); 0.90 (d, 6H, J=7 Hz).

EXAMPLE 4

methyl (R) (−)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate.

By substituting the R-ibuprofen with 0.74 g (2.9 mmol) of R(−)-ketoprofen in the process of Example 3, 0.81 g of (R) (−)-5-[2-(3′-benzoyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione are obtained ([α]_D=−39.5°; c=1% CH₂Cl₂), which, by boiling in methanol yields, after purification by flash chromatography (eluent: n-hexane/ethyl acetate 8:2), 0.49 g (1.56 mmol) of pure methyl (R) (−)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate as a colourless oil, [α]_D=−135°(c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.85-7.40 (m, 9H); 4.0 (q, 1H, J=8Hz); 3.70 (s, 3H); 3.50-3.30 (q, 2H, J=8 Hz); 1.45 (d, 3H, J=8 Hz).

EXAMPLE 5

(S)(+) ethyl-4-[(3′-benzoyl)phenyl]-3-oxopentanoate

(S)(+)-3-[(3′-benzoyl)phenyl]butan-2-one

At room temperature, in an inert-gas atmosphere and under stirring, to a suspension of magnesium ethylate (0.57 g) in 6 mL of anhydrous THF a solution of mono-ethylester malonic acid (1.3 g) in 3 mL of THF is added. After complete solution of the reagents, to the mixture of the complex magnesium-malonic ethylester, by rapid dripping, a solution of S(+) 2-(3-benzoylphenyl) propionylimidazolide (0.83 g) in 10 mL of anhydrous THF is added, prepared in situ by addition of 0.43 g of 1,1′-carbonyldiimidazole to a solution of S(+) 2-(3-benzoylphenyl) propionic acid (0.66 g) in THF. The mixture is stirred for 4 hours, then is acidified by addition of 50% aqueous AcOH (1.2 mL) and is concentrated under vacuum at a small volume and diluted with water. After repeated extractions with ethyl acetate, the organic phases are combined, rinsed with a saturated solution of NaCl, dried on sodium sulfate, and evaporated to dryness to yield, after purification on silica gel, 0.82 g of ethyl (S)(+)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate;
[α]_D=+129° (c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.82-7.45 (m, 9H); 4.1 (q, 1H, J=8 Hz); 3.75 (s, 3H); 3.50-3.25 (q, 2H, J=8Hz); 1.48 (d, 3H, J=8 Hz)
According the same described procedure and starting from the corresponding arylpropionic acids the following 3-oxoesters have been synthesised:

(R)(−) methyl 4-[(4′-benzoyloxy)phenyl]-3-oxopentanoate

¹H-NMR (CDCl₃): δ 8.02 (m, 2H); 7.51 (m, 1H); 7.35 (m, 2H); 7.27 (s, 1H); 7.22 (m, 2H); 3.85 (m, 2H); 3.74 (s, 3H); 3.42-3.37 (q, 2H, J=8 Hz); 2.78 (q, 2H, J=8 Hz); 1.25 (t, 3H, J=8 Hz).

(R)(−) methyl-4-[(4′-isopropylsulfonyloxy)phenyl]-3-oxopentanoate

[α]_D=−184.2° (c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.32 (d, 2H, J=7 Hz); 7.21 (d, 2H, J=7 Hz); 4.1 (q, 1H, J=8 Hz); 3.81 (m, 1H); 3.70 (s, 3H); 3.50-3.30 (q, 2H, J=8 Hz); 1.75 (d, 6H, J=7 Hz); 1.45 (d, 3H, J=8 Hz).

(R)(−) methyl-4- {[4′-(2″-ethyl)phenylsulfonylamino]phenyl}-3-oxopentanoate

[α]_D=−81.3° (c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.32 (d, 2H, J=7 Hz); 7.20 (m, 6H); 6.84 (bs, 1H, SO2NH); 4.05 (q, 1H, J=8 Hz); 3.72 (s, 3H); 3.55-3.35 (q, 2H, J=8 Hz); 2.75 (q, 2H, J=8 Hz); 1.45 (d, 3H, J=8 Hz); 1.22 (t, 3H, J=8 Hz). A solution of 0.4 g of the compound in 1.5 mL of dimethylsulfoxide, to which 2 drops of a saturated aqueous solution of NaCl are added, is heated for 4 hours, under stirring, in a bath at 140-145° C.; after cooling and dilution with water, the mixture is extracted repeately with ethyl acetate. From the combined organic phases, after the usual processing, an oily residue is obtained which, after purification by flash chromatography, yields 0.24 g of S (+)-3-[(3′-benzoyl)phenyl]butan-2-one as a yellow oil; [α]_D=+101° (c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.83 (m, 2H); 7.77 (m, 2H); 7.65 (m, 1H); 7.50-7.45 (m, 4H); 3.85 (q, 1H, J=8 Hz); 2.3 (s, 3H); 1.40 (d, 3H, J=8 Hz).

EXAMPLE 6

(R)(−)-dimethyl 3-(4-isobutylphenyl)-2-oxobut an-1-phosphonate

A solution of (R) (−)-ibuprofen (3.45 g) in ethyl ether, cooled to 5° C., is treated, dropwise, with a 0.6 M solution of diazomethane in ethyl ether, up to a persistent yellow colour. The solvent is removed under vacuum; the residual oil is purified by flash chromatography to yield 3.3 g of methyl (R) (−) 2-(4′-isobutylphenyl)-propionate.
Alternatively, 2.6 g of carbonyldiimidazole are added under stirring to a solution of R(−) ibuprofen (3.45 g) in 10 mL of THF. The mixture is stirred for 1 h, the solvent is evaporated under vacuum, and the residual oil is purified by flash chromatography to yield 4.05 g of (R) (−) 2-(4′-isobutylphenyl)-propionylimidazolide.
In an inert-gas atmosphere, a solution of butyl lithium (1.56 M; 13.3 mL, 0.027 mol) in hexane is added dropwise to a solution of dimethyl methylphosphonate (3.69 g; 0.03 mol) in anhydrous THF (10 mL) cooled to −70° C. The mixture is stirred for 15 min before addition, dropwise, of a solution in anhydrous THF (10 mL) of methyl ester or of imidazolide, prepared as previously described.
Upon completion of the dripping step, the reaction mixture is kept, under stirring, for 1 h at −70° C. and then for 1 h at room temperature. The mixture is then cooled to −10° C., and 1.8 mL of glacial acetic acid is added dropwise. The solvent is removed under vacuum, the residue is diluted with water, and the mixture is repeatedly extracted with dichloromethane (4×50 mL). The organic extracts are dried on sodium sulfate; after evaporation of the solvent, the residue is purified on silica gel, eluted with AcOEt to yield, as a colourless oil, 3.02 g of (R) (−)-dimethyl 3-(4-isobutyl)-2-oxobutan-1-phosphonate.
[α]_D=−171° (c=1; CH₃OH); ¹H-NMR (CDCl₃): δ 7.03 (s, 4H); 4.1-3.9 (dd, 2H, J₁=15 Hz, J₂=8 Hz); 3.8 (s, 3H); 3.70 (m, 1H); 3.65 (s, 3H); 2.55 (d, 2H, J=8 Hz); 1.75 (m, 1H); 1.50 (d, 3H, J=8 Hz); 0.85 (d, 6H, J=7 Hz).

EXAMPLE 7

(R)(−) 2-(4-isobutylphenyl)-7-tert-butoxycarbonylamino-heptan-3-one

A solution of ethyl 5-tert-butoxycarbonylamino-2-ethoxycarbonyl-pentanoate (WO 94/10127) (1.59 g) in 3 mL of methanol is added to 8 mL of a 0.63 N solution of LiOH.H₂O in water/methanol (1:1); the mixture is stirred for 12 h at room temperature. The mixture is diluted with 10 mL of a saturated solution of monosodium phosphate, and the excess of methanol is removed under vacuum. The mixture is extracted with ethyl acetate (2×10 mL); from the organic extracts, combined and dried on sodium sulfate, by evaporation of the solvent 1.4 g (4.8 mmol) of 5-tert-butoxycarbonylamino-2-ethoxycarbonyl-pentanoic acid are obtained.
To a solution of the acid (2.4 mmol) in 8 mL of anhydrous THF 0.27 g (2.4 mmol) of commercially available magnesium ethylate is then added, and the suspension is stirred at room temperature up to complete dissolution of the reagents to form the magnesium complex.
Then a solution of 0.3 g of (R) (−) 2-(4′-isobutylphenyl)-propionylimidazolide is added, and the mixture is stirred for 4 h at room temperature. The mixture is acidified by addition of a few mL of 50% aqueous AcOH, and the solvent is evaporated under vacuum. The residue is repartitioned between water and ethyl acetate to yield, after the usual processing, crude product (0.42 g) of ethyl (R,S)-2-[R-2-(4-isobutyl)-propionyl)-5-tert-butoxycarbonylamino-pentanoate, which is purified by flash chromatography.
A solution of 0.15 g of β-ketoester in DMSO/NaCl/H₂O is then dealkoxydecarboxylated by heating to 135-145° C. to yield 0.08 g of (R) (−) 2-(4-isobutylphenyl)-7-tert-butoxycarbonylamino-heptan-3 -one.
[α]_D{double overscore (.)}−25 (c=1; CH₃OH); ¹H-NMR (CDCl₃); δ 7.25 (s, 4H); 6.35 (bs, 1H, CONH); 3.70 (q, 1H, J=8 Hz); 3.40 (m, 2H); 2.45 (d, 2H, J=7 Hz); 2.31 (m, 2H); 1.85 (m, 1H); 1.75-1.62 (m, 4H); 1.60 (d, 3H, J=7 Hz); 1.45 (s, 9H); 0.94 (d, 6H, J=7 Hz).

EXAMPLE 8

Following the procedure of Example 7, but using as a starting material a monoester of a substituted malonic acid chosen in the group of:

methyl 2-carboxy-propionate;
methyl 2-carboxy-2-phenyl acetate;
methyl 2-carboxy-3-phenyl propionate;
methyl 2-carboxy-3(-pyrid-3-yl) propionate;
methyl 2-carboxy-3-cyclopentyl propionate; the following β-ketoesters were obtained:
methyl(R′, S′)-2-[R-2-(4-isobutylphenyl)-propionyl] propionate;
methyl(R′, S′)-2-[R-2-(4-isobutylphenyl)-propionyl]-2-phenyl acetate;
methyl(R′, S′)-2-[R-2-(4-isobutylphenyl)-propionyl]-3-phenyl propionate;
methyl(R′, S′)-2-[R-2-(4-isobutylphenyl)-propionyl]-3-(pyrid-3-yl propionate;
methyl(R′, S′)-2-[R-2-(4-isobutylphenyl)-propionyl]-3-cyclopentyl propionate; to obtain, after decarboxylation in DMSO/NaCl, the corresponding ketones:

R(−) 2-(4-isobutylphenyl)-pentan-3-one

[α]_D=−36 (c=1; CH₃OH); ¹H-NMR (CDCl₃); δ 7.20 (d, 2H, J=7 Hz); 7.10 (d, 2H, J=7 Hz); 3.70 (q, 1H, J=8 Hz); 2.47 (d, 2H, J=7 Hz); 2.40 (q, 2H, J=7 Hz); 1.82 (m, 1H); 1.55 (d, 3H, J=7 Hz); 0.98 (d, 3H, J=7 Hz); 0.94 (d, 6H, J=7 Hz).

R(−) 2-(4-isobutylphenyl)-4-phenyl-butan-3-one

[α]_D={double overscore (.)}−48.5 (c=1; CH₃OH); ¹H-NMR (CDCl₃); δ 7.35-7.18 (m, 5H); 7.15 (d, 2H, J=7 Hz); 7.05 (d, 2H, J=7 Hz); 3.72 (q, 1H, J=8 Hz); 3.65 (s, 2H); 2.42 (d, 2H, J=7 Hz); 1.80 (m, 1H); 1.60 (d, 3H, J=7 Hz); 0.93 (d, 6H, J=7 Hz).

R(−) 2-(4-isobutylphenyl)-5-phenyl-pentan-3-one

[α]_D{double overscore (.)}−40 (c=1.5; CH₃OH); ¹H-NMR (CDCl₃); δ 7.37-7.20 (m, 5H); 7.10 (d, 2H, J=7 Hz); 7.00 (d, 2H, J=7 Hz); 3.70 (q, 1H, J=8 Hz); 2.88 (m, 2H); 2.75 (m, 2H); 2.45 (d, 2H, J=7 Hz); 1.82 (m, 1H); 1.63 (d, 3H, J=7 Hz); 0.95 (d, 6H, J=7 Hz). R(−) 2-(4-isobutylphenyl)-5-(pyrid-3-yl)-pentan-3-one
[α]_D{double overscore (.)}−89 (c=1; CH₃OH); ¹H-NMR (CDCl₃); δ 8.62 (m, 2H); 7.80 (m, 1H); 7.35 (m, 1H); 7.15 (d, 2H, J=7 Hz); 7.08 (d, 2H, J=7 Hz); 5.35 (t, 2H, J=8 Hz); 5.05 (t, 2H, J=8 Hz); 3.72 (q, 1H, J=8 Hz); 2.42 (d, 2H, J=7 Hz); 1.80 (m, 1H); 1.63 (d, 3H, J=7 Hz); 0.94 (d, 6H, J=7 Hz).

EXAMPLE 9

(R,S) 1-phenyl-4-(4′-isobutylphenyl)-1,3-pentadione

A suspension of 0.55 g of magnesium ethylate in a solution of 1.61 g of benzoylacetic acid is stirred at room temperature, in an inert-gas atmosphere, up to total dissolution of the reagents. A solution of 0.6 g of (R,S)-2-(4′-isobutylphenyl)-propionylimidazolide is added, and stirring is continued overnight at room temperature. The mixture is brought to neutrality by addition of a few drops of 50% aqueous AcOH, and is then evaporated to dryness under vacuum. The residue is repartitioned between water and ethyl acetate. The combined organic phases are dried on sodium sulfate, and evaporated to dryness. The residue is purified by flash chromatography to obtain 0.78 g of (R,S) 1-phenyl-4-(4′-isobutylphenyl)-1,3-pentadione.
¹H-NMR (CDCl₃); δ 7.90 (m, 2H); 7.65 (m, 1H); 7.52 (m, 2H); 7.20 (d, 2H, J=7 Hz); 7.12 (d, 2H, J=7 Hz); 3.77 (s, 2H); 3.68 (q, 1H, J=8 Hz); 2.41 (d, 2H, J=7 Hz); 1.82 (m, 1H); 1.60 (d, 3H, J=7 Hz); 0.95 (d, 6H, J=7 Hz).

EXAMPLE 10

Following the procedure of Example 9, and using a β-ketoacid chosen in the group of acetylacetic acid, 4-phenyl-3-oxo-butyrric acid or nicotinoylacetic acid, in place of benzoylacetic acid, the following are obtained:

(R,S) 5-(4′-isobutylphenyl)-hexan-2,4-dione

¹H-NMR (CDCl₃); δ 7.20 (d, 2H, J=7 Hz); 7.12 (d, 2H, J=7 Hz); 3.75 (s, 2H); 3.65 (q, 1H, J=8 Hz); 2.40 (d, 2H, J=7 Hz); 2.10 (s, 3H); 1.82 (m, 1H); 1.62 (d, 3H, J=7 Hz); 0.94 (d, 6H, J=7 Hz).

(R,S) 1-phenyl-5-(4′-isobutylphenyl)-2,4-hexandione

¹H-NMR (CDCl₃); δ 7.35-7.20 (m, 5H); 7.15 (d, 2H, J=7 Hz); 7.05 (d, 2H, J=7 Hz); 3.75 (s, 2H); 3.68 (q, 1H, J=8 Hz); 3.63 (s, 2H); 2.41 (d, 2H, J=7 Hz); 1.80 (m, 1H); 1.64 (d, 3H, J=7 Hz); 0.95 (d, 6H, J=7 Hz).

(R,S) 1-(pyrid-2-yl)-4-(4′-isobutylphenyl)-1,3-pentadione

¹H-NMR (CDCl₃); δ 8.60 (m, 2H); 7.81 (m, 1H); 7.37 (m, 1H); 7.18 (d, 2H, J=7 Hz); 7.10 (d, 2H, J=7 Hz); 3.70 (q, 1H, J=8 Hz); 3.65 (s, 2H); 2.40 (d, 2H, J=7 Hz); 1.81 (m, 1H); 1.65 (d, 3H, J=7 Hz); 0.95 (d, 6H, J=7 Hz).

EXAMPLE 11

(R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfoxide

A solution of sodium hydride (21 mmol) in dry methylsulfoxide (5 mL) is heated at 60° C., in an inert-gas atmosphere, for 1 h. A solution of 2.2 g (10 mmol) of methyl 2-(4′-isobutylphenyl)-propionate in dry methylsulfoxide is dropped, and stirring is continued for 2 h at 60° C. The mixture is cooled at room temperature, brought to neutrality by addition of AcOH (0.25 mL), and diluted with diethyl ether. 1N HCl is added until pH=2 and CH₂Cl₂and water are added. The two phases are debated and separated; the combined organic phases are dried on sodium sulfate, and evaporated to dryness. The residue is purified by flash chromatography to obtain 0.350 g of (R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfoxide.
¹H-NMR (CDCl₃); δ 7.14 (s, 4H); 3.85 (m, 2H); 3.52 (m, 1H); 2.65+2.54 (s, 3H); 2.47 (d, 2H, J=7 Hz); 1.87 (m, 1H); 1.43 (d, 3H, J=7 Hz); 0.92 (d, 6H, J=7 Hz).
According the same above described procedure and using the corresponding methyl ester of ketoprofen the following compound is obtained:

(R,S) 2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfoxide

¹H-NMR (CDCl₃); δ 7.85-7.60 (m, 4H); 7.52-7.40 (m, 5H); 3.80 (m, 2H); 3.55 (m, 1H); 2.62+2.55 (s, 3H); 2.47 (d, 2H, J=7 Hz); 1.85 (m, 1H); 1.40.(d, 3H, J=7 Hz); 0.94 (d, 6H, J=7 Hz).
According the same above described procedure and using the methyl ester of the corresponding arylpropionic acids and methylsulfone (or phenylsulfone) instead of methylsulfoxide, the following compounds are obtained:

(R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfone

¹H-NMR (CDCl₃); δ 7.18 (s, 4H); 4.18 (m, 2H); 3.90 (m, 1H); 3.10 (s, 3H); 2.40 (d, 2H, J=7 Hz); 1.80 (m, 1H); 1.52 (d, 3H, J=7 Hz); 0.94 (d, 6H, J=7 Hz).

(R,S) 2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfone

¹H-NMR (CDCl₃); δ 7.85-7.60 (m, 4H); 7.52-7.40 (m, 5H); 4.20 (m, 3H); 3.95 (m, 1H); 3.18 (s, 3H); 1.55 (d, 3H, J=7 Hz).

(R,S) 2-(3′-phenoxyphenyl)-3-oxo-butyl, methyl-sulfone

¹H-NMR (CDCl₃); δ 7.25-7.38 (m, 2H); 7.15-7.05 (m, 2H); 7.02 (m, 2H); 6.70-6.60 (m, 2H); 6.55 (s, 1H); 4.21 (m, 3H); 4.15 (m, 1H); 3.20 (s, 3H); 1.58 (d, 3H, J=7 Hz).R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, phenyl-sulfone
¹H-NMR (CDCl₃); δ 8.05 (m, 2H); 7.75 (m, 1H); 7.60 (m, 2H); 7.15 (s, 4H); 4.15 (m, 2H); 3.95 (m, 1H); 2.40 (d, 2H, J=7 Hz); 1.80 (m, 1H); 1.52 (d, 3H, J=7 Hz); 0.94 (d, 6H, J=7 Hz).

EXAMPLE 12

(R)(−)-4-(4′-pyridyl)-2-[(4″-isobutyl)phenyl]butan-3-one

Diisopropylamine (0.17 mL; 1.21 mmol) and sodium hydride (60% in mineral oil, 0.106 mg; 2.66 mmol) are dissolved in dry THF (20 mL) under nitrogen atmosphere; 4-pyridylacetic acid (0.166 g; 1.21 mmol) is added portionwise to the mixture and the mixture refluxed for 15′. After cooling at T=0°-4° C. by an ice-water bath, butyllithium (1.6 M in hexanes, 0.75 mL; 1.21 mmol)) is added to the mixture and, after 30′, a solution of R(−)-2-(4′-isobutylphenyl)propionyl chloride (0.27 g; 1.21 mmol)in dry THF (10 mL) is added dropwise. At the end of the adding, the ice-water bath is removed and the solution is left under stirring overnight at room temperature. The solvent is evaporated under reduced pressure and the residue is diluted with diethyl ether (20 mL), washed with water (3×15 mL), dried over Na2SO4 and evaporated under vacuum to give a dark red oil which is dissolved in 6N HCl (5 mL). The solution is heated at reflux for 2 hours; after cooling at room temperature the solvents are evaporated under vacuum and the residue is purified by flash chromatography to give pure R(−)-4-(4′-pyridyl)-2-[(4″-isobutyl)phenyl]butan-3-one (0.25 g; 0.88 mmol) as pale yellow oil.
[α]_D=148° (c=1; CHCl₃). ¹H-NMR (CDCl₃): δ 8.54 (m, 2H); 7.15-6.90 (m, 6H); 3.85 (m, 1H); 3.72 (q, 2H, J=8 Hz); 2.51 (d, 3H, J=8 Hz); 1.87 (m, 1H); 1.45 (d, 2H, J=7 Hz); 0.92 (d, 6H, J=7 Hz).

EXAMPLE 13

(S) (+) dimethyl 3-(3′-phenoxy-phenyl)-2-oxo-butan-1-phosphonate.

Carbonyldiimidazole (0.18 g) is added to a solution of (S) 2-(3′-phenoxy-phenyl)-propionic acid (0.24 g) in anhydrous THF (5 mL) and is stirred for at least 1 h to form the corresponding imidazolide (Sol. A).
Separately, to a solution of dimethylphosphonoacetic acid (1.7 g) in anhydrous THF (25 mL) magnesium ethylate (0.5 g) is added, and the mixture is stirred for 3 h prior to rapid addition of the solution of imidazolide (Sol. A). The reaction mixture is stirred for 18h at 25° C.
After evaporation of the solvent under vacuum, the residue is partitioned between ethyl acetate and 0.5 N aqueous HCl. The organic phase is washed with water, 5% aqueous sodium bicarbonate and water up to neutrality. After drying on Na₂SO₄, evaporation of the solvent and purification of the residue by flash chromatography on silica gel, 0.26 g of (S) (+) dimethyl 3-(3′-phenoxy-phenyl)-2-oxo-butyl-1-phosphonate are obtained.
[α]_D=+125° (c=1; CH₃OH); ¹H-NMR (CDCl₃); δ 7.25-7.32 (m, 2H); 7.15-7.05 (m, 2H); 7.03 (m, 2H); 6.70-6.65 (m, 2H); 6.50 (s, 1H); 4.15-3.9 (dd, 2H, J₁=15 Hz, J₂=8 Hz); 3.82 (s, 3H); 3.70 (m, 1H); 3.62 (s, 3H); 1.50 (d, 3H, J=8 Hz).

EXAMPLE 14

(R) 2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeramide

Carbonyldiimidazole (1.7 g) is added to a solution of 2.8 g of (R)-indoprofen in 15 mL of (anhydrous) THF, and is stirred for 2 h at room temperature to form the indoprofen imidazolide (Sol. A).
Separately, magnesium ethylate (2.3 g) is added, under stirring, to a solution of 4.2 g of the monoamide of malonic acid in 15 mL of THF. After the total dissolution of the reagents, the solution of the imidazolide is added, and the mixture is stirred for 24 h at room temperature.
After evaporation of the solvent under vacuum, the residue is divided between ethyl acetate and aqueous 0.5 N HCl. The organic phase is washed with water, 5% aqueous sodium bicarbonate and water up to neutrality. After drying on Na₂SO₄, evaporation of the solvent, and purification of the residue by flash chromatography on silica gel, 2.4 g of the amide of

(R) 2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeric acid is obtained

[α]_D=−46° (c=1; CH₃OH); ¹H-NMR (DMSO-d₆); δ 7.70-7.55 (m, 3H); 7.45-7.30 (m, 3H); 7.15 (d, 2H, J=8 Hz); 5.55 (bs, 2H, CONH ₂ ); 4.67 (s, 2H); 3.75 (m, 1H); 3.52 (s, 2H); 1.60 (d, 3H, J=8 Hz).

EXAMPLE 15

(R) 2-(4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeronitrile

Following the procedure of Example 14, and substituting the monoamide of malonic acid with equimolecolar quantities of cyanacetic acid, (R) 2-(4-(1 -oxo-2-isoindolinyl)phenyl]-3-oxo-valeronitrile is obtained.
[α]_D=−21° (c=1; CH₃OH); ¹H-NMR (DMSO-d₆); δ 7.71-7.50 (m, 3H); 7.45-7.30 (m, 3H); 7.18 (d, 2H, J=8 Hz); 4.65 (s, 2H); 3.72 (m, 1H); 3.63 (s, 2H); 1.55 (d, 3H, J=8 Hz).

(R, S) (±)-2-butanone, 3-(3-benzoylphenyl)

ethyl (R, S) (±)-4-(3-benzoyl-phenyl)-3-oxo-pentanoate

(R, S)(±)-1,3-dioxan-4,6-dione-5-[2-(3-benzoylphenyl)-1-oxopropyl]-2,2-dimethyl

2. Compounds according to Claim 1, wherein Ar represents phenyl, optionally substituted by one to three substituents, which are the same or different from one another, selected from:

halogens, C₁-C₄-alkyl, C₁-C₄-alkoxy, hydroxy, C₁-C₄-acyloxy, phenoxy, cyano, nitro, amino, C₁-C₄-acylamino, halogen-C₁-C₃-alkyl, halogen C₁-C₃-alkoxy, benzoyl, or a residue 4-isobutyl-phenyl, 3-benzoylphenyl, 5-benzoyl-2-acetoxy-phenyl, 3-phenoxy-phenyl, 5-benzoyl-2-thiophenyl, 4-thienoyl-phenyl, 1-oxo-2-isoindolinyl-phenyl, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl, 6-methoxy-β-naphthyl, 1-hydroxy-phenyl-1-methyl, or a residue of formula III:

wherein A is benzyl, phenoxy, benzoyl, benzoyloxime, 1-hydroxy-phenyl-1-methyl, B is hydroxy, C₁-C₄-acyloxy or a group of formula —O—C(═S)—N(CH₃)₂, or —S—C(═O)—N(CH₃)₂.
3. Compounds according to Claim 2 wherein Ar is the residue 4-(2-methyl-propyl)-phenyl, 3-phenoxy-phenyl, 3-benzoylphenyl, -2-[4-(1-oxo-2-isoindolinyl)phenyl], 5-benzoyl-thien-2-yl or 4-thienoyl-phenyl.
4. Compounds according to any one of Claims 1 to 3, wherein the steric configuration of the carbon atom to which the residue Ar is bound corresponds to the enantiomer (R).
5. (R,S)-1-Arylethylketone compounds of formula I and their single (R) and (S) enantiomers:

wherein:
Ar is an aryl group;
Ra and Rb are independently chosen in the group of hydrogen, linear or branched C₁-C₆alkyl, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₁-C₄-alkylphenyl, C₁-C₄-alkyl(α-or β-naphthyl), C₁-C₄-alkyl(2,3,4-pyridyl), cyano (—CN), carboxyamide, carboxyl or carboxyesters of formula CO₂R″ wherein R″ is the residue of a linear or branched C₁-C₆aliphatic alcohol, a phosphonate PO(OR″)₂wherein R″ is as defined above, a group of formula di—X—(CH₂)_n-Z, wherein X is a CO, SO, SO₂group; Z is H, tert-butyl, isopropyl, CO₂R″, CN, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₃-C₆cycloalkyl, NH-BOC, NH₂; n is zero or an integer from 1 to 3;
or Ra and Rb, with the carbon atom to which they are bound, form a cyclic residue 4,6-dioxo-1,3-dioxanyl-2,2-disubstituted of formula II:

wherein R′ is methyl or ethyl, or the two groups R′ form a cyclohexane or cyclopentane ring;
for use as medicaments.
6. Compounds according to Claim 5 for use as inhibitors of IL-8 induced chemotaxis of human PMNs.
7. Pharmaceutical compositions containing a compound according to any one of Claims 1 to 6 in admixture with a suitable carrier thereof.
8. Use of the compounds according to any one of Claims 1 to 6 in the preparation of medicaments for the treatment psoriasis, rheumatoid arthritis, ulcerative cholitis, acute respiratory distress syndrome (ARDS), idiopathic fibrosis, glomerulonephritis, bollous pemphigo and for the prevention and the treatment of damages caused by ischemia and reperfusion.
9. Process for the preparation of compounds according to any one of Claims 1 to 6 comprising the reaction of an activated 2-arylpropionic acid of formula (IV)

wherein
Ar is an aryl group and Y is a residue activating the carbonyl, such as halogen, 1-imidazolyl, pivaloyl, C₁-C₃-alkoxycarbonyl, succinyloxy, benzo-triazol-1-yloxy with a carbanion of formula V:

wherein:
when R′a is the residue of a complex between a carboxyl and magnesium ethoxide, R′b is CO₂R″, CONH₂, CN, PO(OR″)₂or —X—(CH₂)_n-Z′, where X is as defined previously; Rc is H or —(CH₂)_n-Z′, where Z′ is H, tert-butyl, isopropyl, CO₂R″, CN, phenyl, α- or β-naphthyl, 2,3,4-pyridyl, C₃-C₆cycloalkyl, NH-BOC;
when R′a is hydrogen and Rc is hydrogen or a —(CH₂)_n-Z′ radical, as defined above, R′b is phosphonate PO(OR″)₂, CO₂R″, or R′a and R′b with the carbon atom to which they are bound, form the carbanion of 2,4-dioxo-1,3-dioxanyl of formula Va:

wherein R′ is methyl or ethyl, or the two groups R′ form a cyclohexane or cyclopentane ring.

Claims

1. A method for making a medicament comprising admixing (R,S)-1-Arylethylketone compounds of formula I and their single (R) and (S) enantiomers:

wherein:

Ar represents phenyl, optionally substituted by one to three substituents, which are the same or different from one another, selected from:

halogens, C₁-C₄-alkyl, C₁-C₄-alkoxy, hydroxy, C₁-C₄-acyloxy, phenoxy, cyano, nitro, amino, C₁-C₄-acylamino, halogen-C₁-C₃-alkyl, halogen C₁-C₃-alkoxy, benzoyl;

or Ar represents 4-thienoyl-phenyl, 4-(1-oxo-2-isoindolinyl)-phenyl, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl, 6-methoxy-β-naphthyl, 1 -hydroxy-phenyl-1-methyl;

or Ar represents a residue of formula III:

wherein A is benzyl, phenoxy, benzoyl, benzoyloxime, 1-hydroxy-phenyl-1-methyl, B is hydroxy, C₁-C₄-acyloxy or a group of formula —O—C(═S)—N(CH₃)₂, or —S—C(═O)—N(CH₃)₂;

Ra and Rb are independently chosen in the group of hydrogen, linear or branched C₁-C₆alkyl, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₁-C₄-alkylphenyl, C₁-C₄-alkyl(α-or β-naphthyl), C₁-C₄-alkyl(2,3,4-pyridyl), cyano (—CN), carboxyamide, carboxyl or carboxyesters of formula CO₂R″ wherein R″ is the residue of a linear or branched C₁-C₆aliphatic alcohol, a phosphonate PO(OR″)₂wherein R″ is as defined above, a group of formula —X—(CH₂)_n-Z, wherein X is a CO, SO, SO₂group; Z is H, tert-butyl, isopropyl, CO₂R″, CN, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₃-C₆cycloalkyl, NH-BOC, NH₂; n is zero or an integer from 1 to 3;

or Ra and Rb, with the carbon atom to which they are bound, form a cyclic residue 4,6-dioxo-1,3-dioxanyl-2,2-disubstituted of formula II:

wherein R″ is methyl or ethyl, or the two groups R′ form a cyclohexane or cyclopentane ring, in an amount effective for the treatment of diseases that involve IL-8 induced human PMNs chemotaxis, together with a pharmaceutically acceptable carrier.

2. The method according to claim 1 wherein Ar represents a residue 4-isobutyl-phenyl, 3-benzoyl-phenyl, 5-benzoyl-phenyl, 2-acetoxy-phenyl, 3-phenoxy-phenyl.

3. The method according to claim 1 or 2 in which the compound is selected from:

methyl (R)(−)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate;

methyl (S)(+)-4-[(4′-isobutyl)phenyl]-3-oxopentanoate;

(R,S) 4-[(4′-isobutyl)phenyl]-3-oxopentanoic acid;

methyl (R)(−)-4-[(3′-benzoyl)phenyl]-3-oxopentanoate;

(R)(−)-3-[(4′-isobutyl)phenyl]butan-2-one;

(S)(+)-3-[(4′-isobutyl)phenyl]butan-2-one;

(R)(−)-3-[(3′-benzoyl)phenyl]butan-2-one;

(R)(−)-dimethyl 3-(4-isobutyl-phenyl)-2-oxobutan-1-phosphonate;

(S)(±)-dimethyl 3-(3′-phenoxy-phenyl)-2-oxo-butyl-1-phosphonate;

(R)(−)-2-(4-isobutylphenyl)-pentan-3-oxopentanoate;

(S)(+) ethyl-4-[(3′-benzoyl)phenyl]-3-oxopentanoate;

(S)(+)-3-[(3′-benzoyl)phenyl]butan-2-one;

(R)(−)-2-(4-isobutylphenyl)-4-phenyl-butan-3-one;

(R)(−)-2-(4-isobutylphenyl)-5 -phenyl-pentan-3 -one;

(R)(−)-2-(4-isobutylphenyl)-5-(pyrid-3-yl)-pentan-3-one;

(R,S) 5-(4′-isobutylphenyl)-hexan-2,4-dione;

(R,S) 1-phenyl-5-(4′-isobutylphenyl)-2 4-hexandione;

(R,S) 1-(pyrid-2-yl)-4-(4′-isobutylphenyl)-1,3-pentadione;

(R) (−) 2-(4-isobutylphenyl)-7-tert-butoxycarbonylamino-heptan-3-one;

(R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfoxide;

(R,S) 2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfoxide;

(R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, methyl-sulfone;

(R,S) 2-(3′-benzoylphenyl)-3-oxo-butyl, methyl-sulfone;

(R,S) 2-(3′-phenoxyphenyl)-3-oxo-butyl, methyl-sulfone;

(R,S) 2-(4′-isobutylphenyl)-3-oxo-butyl, phenyl-sulfone;

(R)(−)-4-(4′-pyridyl)-2-[(4″-isobutyl)phenyl]butan-3-one;

(R) (+)-5-[2-(4-isobutyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione;

(R) (−)-5-[2-(3′-benzoyl-phenyl)-propion-1-yl]-2,2-dimethyl-1,3-dioxan-4,6-dione.

(R)-2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeramide;

(R)-2-[4-(1-oxo-2-isoindolinyl)phenyl]-3-oxo-valeronitrile;

4. A method for preparing a medicament comprising admixing:

(R)(−) methyl 4-[(4′-benzoyloxy)phenyl]-3-oxopentanoate,

(R)(−) methyl-4-[(4′-isopropylsulfonyloxy)phenyl]-3-oxopentanoate and

(R)(−) methyl-4-{[4′-(2″-ethyl)phenylsulfonylamino]phenyl}-3-oxopentanoate, in an amount effective for the treatment of diseases that involve IL-8 induced human PMNs chemotaxis, together with a pharmaceutically acceptable carrier.

5. The method according to claim 1 or 2, wherein the steric configuration of the carbon atom to which the residue Ar is bound corresponds to the enantiomer (R).

6. A pharmaceutical composition comprising (R,S)-1-Arylethylketone compounds of formula I and their single (R) and (S) enantiomers:

wherein:

or Ar represents 4-thienoyl-phenyl, 4-(1-oxo-2-isoindolinyl)-phenyl, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1yl)phenyl, 6-methoxy-β-naphthyl, 1-hydroxy-phenyl-1methyl;

or Ar represents a residue of formula III:

Ra and Rb are independently chosen in the group of hydrogen, linear or branched C₁-C₆alkyl, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₁-C₄-alkylphenyl, C₁-C₄-alkyl(α-or β-naphthyl), C₁-C₄-alkyl(2,3,4-pyridyl), cyano (—CN), carboxyamide, carboxyl or carboxyesters of formula CO₂R″ wherein R″ is the residue of a linear or branched C₁-C₆aliphatic alcohol, a phosphonate PO(OR″)₂wherein R″ is as defined above, a group of formula —X—(CH₂)_n-Z, wherein X is a CO, SO, SO₂group, Z is H, tert-butyl, isopropyl, CO₂R″, CN, phenyl, α-or β-naphthyl, 2,3,4-pyridyl, C₃C₆cycloalkyl, NH-BOC, NH₂; n is zero or an integer from 1 to 3;

wherein R′ is methyl or ethyl, or the two groups R′ form a cyclohexane or cyclopentane ring, in admixture with a suitable carrier thereof.

7. (canceled)

8. A method for treatment of a disease selected from the group consisting of psoriasis, rheumatoid arthritis, ulcerative cholitis, acute respiratory distress syndrome (ARDS), idiopathis fibrosis, glomerulonephritis, bollous pemphigo or for the prevention and the treatment of tissue damage caused by ischemia and reperfusion, comprising administering the pharmaceutical composition of claim 6 to a subject requiring treatment for said disease or for ischemia and reperfusion.